source
- FDA panel rejects Capricor's Duchenne drug, citing insufficient efficacy dataThe U.S. Food and Drug Administration advisory committee voted 9-to-3 against a Capricor Therapeutics candidate for Duchenne muscular dystrophy. The panel said the clinical data did not provide sub…
- Attovia, Braveheart Bio, and Vogenx aim to raise over $500M through combined IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have each filed IPO paperwork, setting price ranges that together target more than $500 million in gross proceeds from public investors. Braveheart…